Inflammatory bowel disease in children: A pediatrician's perspective

Minerva Pediatrica

Volumn 58, Issue 2, 2006, Pages 139-157

  Cuffari, C ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Child; Inflammatory bowel diseases, diagnosis; Inflammatory bowel diseases, drug therapy

Indexed keywords

AZATHIOPRINE; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CORTICOSTEROID; CYCLOSPORIN; GADOLINIUM; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METHOTREXATE;

ABDOMINAL PAIN; BODY HEIGHT; BODY WEIGHT; BONE MARROW DEPRESSION; CAPSULE ENDOSCOPY; CHROMOSOME 16; CROHN DISEASE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ENTERITIS; ENZYME DEFECT; GENE MUTATION; HEADACHE; HEPATITIS; HOMOZYGOSITY; HUMAN; HYPERTENSION; HYPERTRICHOSIS; KIDNEY FAILURE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITIONAL SUPPORT; OLIGOMERIZATION; OSTEOLYSIS; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PEDIATRICIAN; PUBERTY; RASH; REVIEW; SEROLOGY; SUPERINFECTION; TREMOR; ULCERATIVE COLITIS; VOMITING;

6-MERCAPTOPURINE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIMETABOLITES; CHILD; COLITIS, ULCERATIVE; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ILEUS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MASS SCREENING; MESALAMINE; NOD2 SIGNALING ADAPTOR PROTEIN; RISK FACTORS;

EID: 33745023161     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (136)

1. Seidman EG. Inflammatory Bowel disease. In: Roy CC, Silverman A, Alagille A editors. Clinical Pediatric Gastroenterology. 4th ed. Philadelphia: Mosby; 1993. p. 417-93.
2. Kugathasan S, Judd RH, Hoffmann RG, Heikenen J, Telega G, Khan F et al. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population study. J Pediatr 2003;143:525-31.
3. Kornbluth A, Solomon P, Sachar DB. Crohn's disease. In: Sleisenger MH, Fordtran JS editors. Gastrointestinal diseases. Philadelphia: WB Saunders; 1993. p. 1270-304.
4. Bennet RA, Rubin PH, Present DH. Frequency of inflammatory bowel disease in offspring of couples both presenting with inflammatory bowel disease. Gastroenterology 1991;100:1638-43.
5. Calenda KA, Grand RJ. Clinical manifestations of pediatric inflammatory bowel disease. In: Kirsner JB, Shorter RB editors. Inflammatory Bowel Disease. 4th ed. Baltimore: Williams and Wilkins; 1995. p.380-9.
6. Kirschner BS. Inflammatory bowel disease in children. Pediatr Clin North Am 1988;35:189-208.
7. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 2003;124:521-36.
8. Yang H, McElree C, Roth MP, Shanahan F, Targan SR, Rotter JI. Familial empiric risks for inflammatory bowel disease: differences between Jew and non-Jews. Gut 1993;34:517-24.
9. Fielding JF. The relative risk of inflammatory bowel disease among parents and sibling of Crohn's disease parents. J Clin Gastroenterol 1986;8:655-7.
10. McBride JA, King MJ, Baikie AG. Ankylosing spondylitis and chronic inflammatory bowel diseases of the intestines. BMJ 1963;2:483-6.
11. Price WH. A high incidence of chronic inflammatory bowel disease in patients with Turner's syndrome. J Med Genet 1979;16:263-6.
12. Duerr RH, Chensny LJ. Associations between HLA-DR alleles and subsets of ulcerative colitis defined by extent of colitis. Gastroenterology 1997;112:A963.
13. Hampe J, Stokkers, Nurnberg P, Herrmann T, Theuer D, Scheurlen M et al. Linkage to a susceptibility region on chromosome 12, but not 16 in a North central European family sample by multi-point non-parametric linkage analysis. Gastroenterology 1997;112:A990.
14. Polito JM 2nd, Childs B, Mellits ED, Tokayer AZ, Harris ML, Bayless TM. Crohn's disease: influence of age at diagnosis on site and clinical type of disease. Gastroenterology 1996;111:580-6.
15. Roth MP, Petersen GM, McElree C, Vadheim CM, Panish JF, Rotter JI. Familial recurrence risk estimates of inflammatory bowel disease in Ashkenazi Jews. Gastroenterology 1989;96:1016-20.
16. Harper PC, McAuliffe TL, Becken WL. Crohn's disease in the elderly. A statistical comparison with younger patients matched for sex and duration of disease. Arch Int Med 1986;146:753-5.
17. Polito JM 2nd, Rees RC, Childs B, Mendeloff AI, Harris ML, Bayless TM. Preliminary evidence for genetic anticipation in Crohn's disease. Lancet 1996;347:798-800.
18. Griffiths AM, Harris K, Smith C et al. Is there anticipation in familial Crohn's disease? Gastroenterology 1997;112:A985.
19. Hogot JP, Puig PL, Goer-Rousseau C, Olson JM, Lee JC, Beaugerie L et al. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 1996;379:821-3.
20. Ohmen JD, Yang HY, Yamamoto K, Zhao HY, Ma Y, Bentley LG et al. Susceptibility locus for inflammatory bowel disease on chromosome 16 has a role in Crohn's disease, but not ulcerative colitis. Hum Mol Genet 1996;10:1678-83.
21. Cho JH, Fu Y, Kirschner B, Hanauer SB. Confirmation of susceptibility locus IBD 1 for Crohn's disease on chromosome 16. Gastroenterology 1997; 112: A948.
22. Cavanaugh J, Callen DF, Wilson SR, Stanford PM, Srami ME, Gorska M et al. Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. Ann Hum Genet 1998;62:291-8.
23. Hampe J, Nurnberg P, Raedler A, Lochs H, Schreiber S. Mapping inflammatory bowel disease genes: complications of study design and population structure. Gastroenterology 1997;112:A991.
24. Hofmeister A, Neibergs H, Pokorny R, Heinzelmann M, Galandiuk S. Epidemiological study confirms association of IBD 1 with Crohn's disease. Gastroenterology 1997;112:A997.
25. Brant SR, Panhuysen CI, Bailey-Wilson JE, Rohal PM, Lee S, Mann J et al. Linkage heterogeneity for the IBD 1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology 2000;119:1483-90.
26. Hetland G, Wilker HG. Antigen 85C in mycobacterium bovis, BCG and M. tuberculosis promotes moncyte-CR3 mediated uptake of microbeads coated with mycobacterial products. Immunology 1994;82:445-9.
27. Maloney MD, Lingwood CA. CD19 has a potential CD77 binding site with sequence similarity to verotoxin cell adhesion and enterohemorrhagic E. coli pathogenesis. J Exp Med 1994;180:191-201.
28. Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
29. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-6.
30. Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J, Aimer S et al. CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002;70: 845-57.
31. Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR et al. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 2002;122:854-66.
32. Tsironi E, Feakins RM, Probert CC, Rampton DS, Phil D. Incidence of inflammatory bowel disease is rising and abdominal tuberculosis is falling in Bangladeshis in East London, United Kingdom. Am J Gastroenterol 2004;99:1749-55.
33. Podolsky D. Inflammatory bowel disease. N Engl J Med 2002;347:417-29.
34. Zareie M, Singh PK, Irvine EJ, Sherman PM, McKay DM, Perdue MH. Monocyte/macrophage activation by normal bacteria and bacterial products: implications for altered epithelial function in Crohn's disease. Am J Pathol 2001;158:1101-9.
35. Desreumaux P, Colombel JF. Intestinal flora and Crohn's disease. Ann Pharm Fr 2003;61:276-81.
36. Tomkins AM, Bradley AK, Oswald S, Drasar BS. Diet and the fecal microflora of infants, children and adults in rural Nigeria and urban UK. J Hyg 1981;86:285-93.
37. Yang SK, Loftus EV, Sandborn WJ. Epidemiology of inflammatory bowel disease in Asia. Infl Bowel Dis 2001;7:260-70.
38. Shanahan F. Making microbes work for mankind - clever trick or a glimpse of the future for IBD treatment? Gastroenterology 2004;127:667-8.
39. Ekbom A, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a case-control study. Am J Epidemiol 1990;132: 1111-9.
40. Ekbom A, Daszak PS, Kraaz W, Wakefield AJ. Crohn's disease following measles virus exposure in utero: risk estimates and clinical characteristics. Gastroenterology 1996;110:A902.
41. Wakefield AJ, Pittilo RM, Simm R, Cosby SL, Stephenson JR, Dhillon AP et al. Evidence of persistent measles virus infection in Crohn's disease. J Med Virol 1993;39:345-53.
42. Lewin J, Dhillon AP, Sim R, Mazure G, Pounder RE, Wakefield AJ. Persistent measles virus infection of the intestine: confirmation by immunogold electron microscopy. Gut 1995;36:564-9.
43. Gurbindo C, Seidman EG. Gastrointestinal manifestations of primary immunodeficiency disorders. In: Walker WA, Durie PR, Hamilton JR, Walker-Smith JA, Watkins B editors. Pediatric Gastrointestinal Disease Pathophysiology, Diagnosis, Management. 2nd ed. St. Louis: Mosby CV; 1996. p. 585-605.
44. D'Agata ID, Paradis K, Chad Z, Bonny Y, Seidman E. Leucocyte adhesion deficiency presenting as a chronic ileocolitis. Gut 1996;39:605-8.
45. Schinella RA, Greco A, Cobert BL, Denmark LW, Cox RP. Hermansky-Pudlak syndrome with granulomatous colitis. Ann Intern Med 1980;92:20-23.
46. Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 1995;105: 681-91.
47. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease. Gastroenterology 1988;95: 1523-7.
48. Attard TM, Horton S, DeVito S, Oliva-Hemker M, Thompson R, Cuffari C. Pediatric jejunoileitis: a severe Crohn's disease phenotype that requires intensive nutritional support. Inflamm Bowel Dis 2004;10:357-60.
49. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
50. Motil KJ, Grand RJ. Nutritional management of inflammatory bowel disease. Pediatr Clin North Am 1985;32:447-69.
51. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
52. Cuffari C, Bayless TM. Crohn's Disease: influence of age at onset on clinical phenotype. Gastroenterol Int 1997;10:89-98.
53. Grimm I, Friedman L. Inflammatory bowel disease in the elderly. Gastroenterol Clin North Am 1990;19:361-89.
54. Shashishar H, Integlia M, Grand R. Clinical manifestations of pediatric inflammatory bowel disease. In: Kirsner J editor. Inflammatory Bowel Disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 326-41.
55. Kirschner B. The medical management of inflammatory bowel disease in children. In: Kirsner J editor. Inflammatory Bowel Disease. 5th ed. Philadelphia: WB Saunders; 2000. p. 578-97.
56. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33.
57. Hyams J, Davis P, Grancher K, Lerer T, Justinich C, Markowitz J. Clinical outcome of ulcerative colitis in children. J Pediatr 1996;129:81-8.
58. Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Infl Bow Dis 2006. In press.
59. Hassan K, Cowan FJ, Jenkins HR. The incidence of childhood inflammatory bowel disease in Wales. Eur J Pediatr 2000;159:261-3.
60. Moum B, Ekbom A, Vatn MH, Aadland E, Sauar J, Lygren I et al. Inflammatory bowel disease: re-evaluation of the diagnosis in a prospective population based study in South Eastern Norway. Gut 1997;40:328-32.
61. Meucci G, Bortoli A, Riccoli FA, Girelli CM, Radaelli F, Rivolta R et al. Frequency and clinical evolution of indeterminate colitis: a retrospective multicenter study in Northern Italy. Eur J Gastroenterol Hepatol 1999;11: 909-13.
62. Burakoff R. Indeterminate colitis: clinical spectrum of disease. J Clin Gastroenterol 2004;38 (5 Suppl): S41-S43.
63. Notteghem B, Salomez JL, Gower-Rousseau C, Marti R, Lemahieu M, Nuttens MC et al. [What is the prognosis in unclassified colitis? Results of a cohort study of 104 patients in the Northern-Pas-de-Calais region] Gastroenterol Clin Biol 1993;17: 811-5. French.
64. Lindberg E, Lindquist B, Holmquist L, Hildebrand H. Inflammatory bowel disease in children and adolescents in Sweden.: 1984-1995. J Pediatr Gastroenterol Nutr 2000;30:259-64.
65. Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V, Changes in extent of ulcerative colitis-a study on the course and prognostic factors. Scand J Gastroenterol 1996;31:260-6.
66. Koltum WA, Schoetz DJ, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC. Indeterminate colitis predisposes to perineal complications after ileal pouch-anal anastomosis. Dis Colon Rectum 1991;34:857-60.
67. Kangas E, Matiakinen M, Matilla J. Is indeterminate colitis Crohn's disease in long term follow up? Int Surg 1994;79:120-3.
68. Guindi M, Riddell RH. Indeterminate Colitis. J Clin Pathology 2004;57:1233-44.
69. Winter HS, Landers CJ, Winkelstein A, Vidrich A, Targan SR. Anti-neutrophil cytoplasmic antibodies in children with ulcerative colitis. J Pediatr 1994;124:707-11.
70. Dubinsky MC, Ofman JJ, Urman M, Targan SR, Seidman EG. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol 2001;96:758-65.
71. Joossens S, Reinisch W, Vermiere S, Sendid B, Poulain D, Peeters M et al. The value of ASCA and ANCA in IC: a prospective follow up study. Gastroenterology 2002;122:1242-7.
72. Vasiliauskas EA, Kam LY, Karp LC, Gaiermie J, Yang H, Targan SR. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47:487-96.
73. Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol 2006;101:360-7.
74. Jamieson DH, Shipman PJ, Israel DM, Jacobson K. Comparison of multidetector CT and barium studies of the small bowel: inflammatory bowel disease in children. AJR Am J Roentgenol 2003;180:1211-6.
75. Horton KM, Fishman EK. The current status of multi-detector row CT and three-dimensional imaging of the small bowel. Radiol Clin North Am 2003;41:199-212.
76. Charron M, del Rosario FJ, Kocoshis SA. Pediatric inflammatory bowel disease: assessment with scintigraphy with 99mTc white blood cells. Radiology 1999;212:507-13.
77. Charron M. Pediatric inflammatory bowel disease imaged with Tc-99m white blood cells. Clin Nucl Med 2000;25:708-15.
78. Davison SM, Chapman S, Murphy MS. 99mTc-HMPAO leucocyte scintigraphy fails to detect Crohn's disease in the proximal gastrointestinal tract. Arch Dis Child 2001;85:43-6.
79. Haber HP, Busch A, Ziebach R, Dette S, Ruck P, Stern M. Ultrasonographic findings correspond to clinical, endoscopic, and histologic findings in inflammatory bowel disease and other enterocolitides. J Ultrasound Med 2002;21:375-82.
80. Van Oostayen JA, Wasser MN, van Hogezand RA, Griffioen G, de Roos A. Activity of Crohn disease assessed by measurement of superior mesenteric artery flow with Doppler US. Radiology 1994;193:551-4.
81. Potthast S, Rieber A, Von Tirpitz C, Wruk D, Adler G, Brambs HJ. Ultrasound and magnetic resonance imaging in Crohn's disease: a comparison. Eur Radiol 2002;12:1416-22.
82. Maccioni F, Viscido A, Broglia L, Marrollo M, Masciangelo R, Caprilli R et al. Evaluation of Crohn disease activity with magnetic resonance imaging. Abdom Imaging 2000;25:219-28.
83. Low RN, Francis IR. MR imaging of the gastrointestinal tract with i.v., gadolinium and diluted barium oral contrast media compared with unenhanced MR imaging and CT. AJR Am J Roentgenol 1997;169:1051-9.
84. Darbari A, Sena L, Argani P, Oliva-Hemker M, Thompson R, Cuffari C. Gadolinium-enhanced magnetic resonance imaging (G-MRI) in diagnosing pediatric inflammatory bowel disease. Inflamm Bowel Dis 2004;10:67-72.
85. Linder J, Cheruvattath R, Truss C, Wilcox CM. Diagnostic yield and clinical implications of push enteroscopy: results from a nonspecialized center. J Clin Gastroenterol 2002;35:383-6.
86. Darbari A, Kalloo AN, Cuffari C. Diagnostic yield, safety and efficacy of push enteroscopy in pediatrics. Gastrointest End 2006. In press.
87. Ginsberg GG, Barkun AN, Bosco JJ, Isenberg GA, Nguyen CC, Petersen BT et al. Wireless capsule endoscopy: August 2002. Gastrointest Endosc 2002;56: 621-4.
88. Iddan G, Meron G, Glukhovsky A, Swain P. Wireless capsule endoscopy. Nature 2000;405:417.
89. Fireman Z, Mahajna E, Broide E, Shapiro M, Fich L, Sternberg A et al. Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut 2003;52:390-2.
90. Appleyard M, Fireman Z, Glukhovsky A, Shreiver R, Kadirkamanathan S, Lavy A et al. A randomized trial comparing wireless capsule endoscopy with push enteroscopy for the detection of small-bowel lesions. Gastroenterology 2000;119:1431-8.
91. Liangpunsakul S, Chadalawada V, Rex DK, Maglinte D, Lappas J. Wireless capsule endoscopy detects small bowel ulcers in patients with normal results from state of the art enteroclysis. Am J Gastroenterol 2003;98:1295-8.
92. Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev Gastroenterol Disord 2003;3:81-92.
93. Singleton JW, Hanauer SB, Gitnick GL, Peppercorn MA, Robinson MG, Wruble LD et al. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16 week trial. Pentasa Crohn's disease study group. Gastroenterology 1993;104:1293-301.
94. Wilding IR, Kenyon CJ, Hooper G. Gastrointestinal spread of oral prolonged release mesalazine microgranules doses as either tablets or sachet. Aliment Pharmacol Ther 2000;14:163-9.
95. Sandborn W, Hanauer SB. Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther 2003;17: 29-42.
96. Fallingborg J, Christensen LA, Jacobsen BA, Rasmussen SN. Very low intraluminal colonic pH in patients with active ulcerative colitis. Dig Dis Sci 1993;38:1989-93.
97. Summer RW, Switz DM, Sessions JT Jr, Becktel JM, Best WR, Kern F Jr et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979;77:847-69.
98. Sutherland L, MacDonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003;(3):CD000543.
99. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-2.
100. Lewis JD. How safe are the safest IBD drugs? Gastroenterology 2003;124:1986-7; discussion 1987-8.
101. Hyams JS, Moore RE, Leichtner AM, Carey DE, Goldberg BD. Relationship of type I procollagen to corticosteroid therapy in children with inflammatory bowel disease. J Pediatr 1988;112:893-8.
102. Modigliani R, Mary JY, Simon JF, Cortot A, Soule JC, Gendre JP et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990;98:811-8.
103. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999;94:878-83.
104. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.
105. Pearson DC, May GR, Fick GH, Sutherland SR. Azathioprine and 6-mercaptopurine in Crohn's disease, a meta-analysis. Ann Intern Med 1995;122: 132-42.
106. Fairchild CR, Maybaum J, Kennedy KA. Concurrent unilateral chromatid damage and DNA strand breaks in response to 6-thioguanine treatment. Biochem Pharmacol 1986;35:3533-41.
107. Lennard L. The clinical pharmacology of 6-mercaptopurine in acute lymphoblastic leukemia. Eur J Clin Pharmacol 1992;43:329-39.
108. Lennard L, Lilleyman JS. Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 1989;7:1816-23.
109. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A longterm, randomized, double-blind study. N Engl J Med 1980;302:981-7.
110. Ewe K, Press AG, Singe CC, Stufler M, Ueberschaer B, Hommel G et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993;105:367-72.
111. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995;37:674-8.
112. Verhave M, Winter HS, Grand RJ. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatr 1990;117:809-14.
113. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99: 1347-51.
114. Camma C, Giunta M, Rosselli M, Cottone M. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 1997;113:1465-73.
115. Cuffari C, Theoret Y, Latour S, Seidman EG. 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-6.
116. Dubinsky MC, Lamothe S, Yang HY. Optimizing and individualizing 6-MP therapy in IBD: The role of 6-MP metabolite levels and TPMT genotyping. Gastroenterology 2000;118:705-13.
117. Achar JP, Stevens T, Brzezinski A, Seidner D, Lashner B. 6-thioguanine levels versus white blood cell counts in guiding 6-mercaptopurine and azathioprine therapy. Am J Gastroenterol 2000;95:A272.
118. Cuffari C, Hunt S, Bayless TM. Utilization of erythrocyte 6-thioguanine metabolite levels to optimize azathioprine therapy in patients with IBD. Gut 2001;48: 642-6.
119. Cuffari C, Dassopoulos T, Turnbough T, Thompson RE, Bayless TM. Thiopurine methyl transferase activity influences clinical response to azathioprine therapy in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-7.
120. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short-and long-term toxicity. Ann Intern Med 1989;111:641-9.
121. Black AJ, McLeod HL, Capell HA. Thiopurine methyl transferase predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129: 716-8.
122. McLeod HL, Krynetski EY, Relling MV, Evans WE. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14:567-72.
123. Feagan BG, Rochon J, Fedorak RN, Irvine EJ, Wild G, Sutherland L et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995;332:292-7.
124. Mack D, Young R, Kaufman SS, Ramey L, Vanderhoof JA. Methotrexate in patients with Crohn's disease after 6-mercaptopurine. J Pediatr 1998;132:830-5.
125. Gohkale R, Kirschner BS. Methotrexate therapy in children with severe Crohn's disease: preliminary results. Gastroenterology 1996;110:A916.
126. Kahan BD. Cyclosporine. N Engl J Med 1989;321: 1725-38.
127. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994;330:1841-5.
128. Treem WR, Davis PM, Hyams JS. Cyclosporine treatment of severe ulcerative colitis in children. J Pediatr 1991;119:994-97.
129. Mahdi G, Israel D, Hassall D. Cyclosporine and 6-mercaptopurine for active refractory Crohn's colitis in children. Am J Gastroenterol 1996;91:1355-8.
130. Sternthal M, George A, Kornbluth A, Lichtiger S, Present D. Toxicity associated with the use of cyclosporin in patients with inflammatory bowel disease. Gastroenterology 1996;110:A1019.
131. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T et al. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N Engl J Med 1997;337:1029-35.
132. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF et al. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002;359:1541-9.
133. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
134. Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2001;(3): CD000542
135. Papadopoulou A, Holden CE, Paul L, Sexton E, Booth IW. The nutritional response to home enteral nutrition in childhood. Acta Paediatr 1995;84:528-31.
136. Ozuner G, Fazio VW, Lavery IC, Milsom JW, Strong SA. Re-operative rates for Crohn's disease following stricturoplasty. Did Colon Rectum 1996;39:1199-203.